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ABSTRACT
The multi-modular glycoprotein thrombospondin-1 (TSP-1) is considered as a 
key actor within the tumor microenvironment. Besides, TSP-1 binding to CD47 is 
widely reported to regulate cardiovascular function as it promotes vasoconstriction 
and angiogenesis limitation. Therefore, many studies focused on targeting TSP-
1:CD47 interaction, aiming for up-regulation of physiological angiogenesis to enhance 
post-ischemia recovery or to facilitate engraftment. Thus, we sought to identify an 
innovative selective antagonist for TSP-1:CD47 interaction. Protein-protein docking 
and molecular dynamics simulations were conducted to design a novel CD47-derived 
peptide, called TAX2. TAX2 binds TSP-1 to prevent TSP-1:CD47 interaction, as revealed 
by ELISA and co-immunoprecipitation experiments. Unexpectedly, TAX2 inhibits 
in vitro and ex vivo angiogenesis features in a TSP-1-dependent manner. Consistently, 
our data highlighted that TAX2 promotes TSP-1 binding to CD36-containing complexes, 
leading to disruption of VEGFR2 activation and downstream NO signaling. Such 
unpredicted results prompted us to investigate TAX2 potential in tumor pathology. 
A multimodal imaging approach was conducted combining histopathological 
staining, MVD, MRI analysis and μCT monitoring for tumor angiography longitudinal  
follow-up and 3D quantification. TAX2 in vivo administrations highly disturb syngeneic 
melanoma tumor vascularization inducing extensive tumor necrosis and strongly 
inhibit growth rate and vascularization of human pancreatic carcinoma xenografts 
in nude mice.
INTRODUCTION
Besides its architectural role, extracellular matrix 
(ECM) is commonly known to be involved in a wide 
range of physiological and pathological functions [1], 
with cell-ECM interaction actively taking part in cancer 
progression [2]. ECM is composed of a hydrated ground 
substance of glycosaminoglycans and proteoglycans, 
in which fibrous proteins and associated glycoproteins 
are embedded. Among them, thrombospondins (TSPs) 
consist of a family of five members with TSP-1 first 
identified in 1978 from human blood platelets [3]. 
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TSP-1 is a ubiquitously expressed multimodular protein 
of high molecular weight secreted as a disulfide-linked 
450 kDa homotrimer. The ability of TSP-1 to bind a 
wide variety of ligands such as cell membrane receptors 
or ECM molecules allows it to mediate cell-cell and 
cell-ECM interactions [4], thus conferring multifaceted 
functionalities. TSP-1 modulates tumor cell adhesion [5], 
proliferation [6], survival or apoptosis [7–9]. Furthermore, 
TSP-1 is also involved in inflammation, immune response 
[10] and is widely known as an endogenous inhibitor of 
angiogenesis [11–14] by interacting with stromal cells.
The globular carboxy-terminal cell-binding domain 
(CBD) of TSP-1 binds the cell surface receptor CD47, 
also called IAP (integrin-associated protein) [15]. CD47 
is a ubiquitous 50 kDa five-spanning membrane receptor 
that belongs to the immunoglobulin superfamily. While 
TSP-1:CD47 interaction is identified as a key signaling 
integrator of tumor progression [4], its contribution 
remains somewhat controversial as TSP-1 exhibits a 
pleiotropic activity within the tumor microenvironment. 
TSP-1 is overexpressed in tumor stroma [16] and could 
sustain cancer cell invasion by increasing ECM-associated 
proteolytic activity through CD47 ligation [17]. Moreover, 
TSP-1 was reported to inhibit apoptosis and to promote 
drug resistance in thyroid carcinoma cells [7, 8] and was 
associated with poor prognosis and recurrence in several 
cancers [18–20]. However, concerns should be raised 
about a possible pro-tumor role for TSP-1, as a number 
of contrasting results were obtained considering other 
cancer types. Indeed, TSP-1 is down-regulated in taxane 
resistant cells due to its ability to induce apoptosis via 
CD47 ligation [21], and TSP-1 binding to CD47 is also 
recognized to induce killing of breast cancer cells [9]. 
Besides, TSP-1 could delay tumor growth by indirectly 
altering tumor blood flow [22]. Finally, TSP-1 as well as 
proteolytic fragments or synthetic peptides derived from 
TSP-1 have anti-angiogenic and anti-neoplasic potentiality 
[16, 23, 24].
In addition to its major contribution in cancer 
progression [7, 8, 16, 17, 21], TSP-1 appears to be highly 
implicated in the regulation of cardiovascular functions 
as it promotes vasoconstriction and limits angiogenesis 
[11, 12]. The anti-angiogenic activity of TSP-1 is mainly 
mediated via binding to CD47, resulting in disruption 
of CD47 association with VEGFR2 [14] and inhibition 
of NO-induced activation of guanylate cyclase [25]. 
Therefore, particular attention was paid over recent 
years to identify new therapeutic tools antagonizing 
TSP-1:CD47 in the purpose of restoring blood flow and 
tissue perfusion. Indeed, antibody blockade of CD47 
as well as morpholino suppression of CD47 expression 
yields promising results regarding graft reperfusion and 
survival, as demonstrated by pre-clinical trials performed 
in mouse [26], rat [27] and porcine [28] models.
We previously characterized the molecular interface 
between TSP-1 CBD and CD47 using a molecular docking 
approach [29] since the crystallographic structure of this 
complex has not been resolved so far. In the present study, 
original molecular modeling approach led to the design 
of a new peptide mimicking this region and aiming to 
functionally antagonize the protein:protein interaction. 
Contrary to our initial expectation, this peptide exhibited 
anti-angiogenic properties in vitro and ex vivo by 
inhibiting TSP-1 binding to CD47 in primary endothelial 
cells. This unexpected result prompted us to investigate 
the biological consequences of peptide treatment in the 
context of tumor pathology. Using multimodal and multi-
scale imaging approaches from in silico to in vivo, we 
evidenced that this CD47-derived peptide disrupts tumor 
angiogenesis in several experimental models and reveals 
exciting anti-tumor properties.
RESULTS
Design of peptides derived from the TSP-1 
binding sequence of CD47
We recently demonstrated by using both normal 
mode analyses and energy minimizations that TSP-1 
CBD can self-open, requiring disruption of an electrostatic 
scratch between R136 and D185 and leading to the solvent 
exposure of the CD47-interacting sequence RFYVVMWK 
[29] (Supplementary movie 1). These preliminary results 
allowed conducting molecular docking experiments 
between the extracellular domain of CD47 and an open 
conformation of the TSP-1 CBD (Fig. 1A). We thus 
identified the SQLLKGD receptor sequence as putatively 
involved in the TSP-1:CD47 interaction and proposed 
two CD47-derived dodecapeptides (called TAX2) that 
could bind TSP-1: the linear IEVSQLLKGDAS and its 
cyclic disulfide analogue CEVSQLLKGDAC. Structural 
alignments showed that PEP-FOLD predicted structures 
of both linear and cyclic TAX2 perfectly mimic the 
helical folding of the sequence in native CD47 (Fig. 1B). 
As shown in Figs. 1C and 1D, molecular dynamics 
experiments highlighted that the interacting sequence is 
less stretchy in the cyclic peptide. This correlates with 
increased stability over time and a conservation of the 
helical native conformation, suggesting an increased 
ability of cyclic TAX2 to bind TSP-1 CBD compared 
to the linear analogue. These data led us to favor the 
cyclic form of the peptide throughout our study. Docking 
experiments were also conducted between cyclic TAX2 
and TSP-1 revealing that the CD47-derived peptide binds 
open TSP-1 CBD in a very similar way as the entire 
receptor (Fig. 1E). This suggests that the theoretically-
predicted CD47-derived peptide might bind TSP-1 to 
antagonize TSP-1:CD47 interaction.
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Figure 1: Identification and characterization of TAX2 peptides targeting the CD47-binding domain of TSP-1. A. Left 
panel. Result of rigid protein-protein molecular docking between an open conformation of TSP-1 CBD (MRMS = 2 Å; represented with a 
solvent-accessible surface on the protein) and the extracellular domain of CD47 (PDB ID code 2JJS, chain C). Solvent-accessible surface 
of RFYVVMWK interaction sequence on TSP-1 (red) is highlighted, as well as R136 and D185 residues allowing TSP-1 opening (O is red, 
N is blue, C is cyan). Right panel is a focus on the interaction region showing lateral chains of CD47 binding sequence IEVSQLLKGDAS 
(blue). B. Structural alignments of TAX2 predicted structures with CD47 extracellular domain. Top panel represents alignment of linear 
TAX2 (IEVSQLLKGDAS). Bottom panel represents alignment of the cyclic analogue (CEVSQLLKGDAC). Calculated RMSD values are 
indicated. C. Stable structure of TAX2 cyclopeptide as observed along 50 ns molecular dynamics simulation trajectory, highlighting that 
flexibility of the peptide is reduced to the disulfide bridge. D. RMSD from linear TAX2 (black line) and cyclic TAX2 (blue line) starting 
structures along the 50 ns simulation. Horizontal dotted line, mean. E. Result of molecular docking between minimized TAX2 cyclopeptide 
(represented as its secondary structure with lateral chains) and the open TSP-1 CBD. F. Thrombospondin from human platelets (5 μg/mL)  
was immobilized on ELISA microtiter plates and blocked with 1% (w/v) BSA. Biotinylated scrambled peptide (mentioned as Ctrl, 10 μg/mL),  
biotinylated TAX2 peptide (10 μg/mL) or non-labeled TAX2 competitor (1 mg/mL) were incubated in buffer containing 0.5% (w/v) BSA 
for 3 h at room temperature. Thrombospondin-bound biotin-labeled peptides were then quantified as described in Materials and Methods 
(see left panel scheme). Results are expressed as percentage of ligand bound to immobilized TSP-1 (mean ± SE, n = 3 independent 
experiments performed in triplicate, t test). G. Binding of biotinylated TAX2 peptide (10 μg/mL) to immobilized TSP-1 was assessed in the 
presence of increasing concentrations of unlabeled TAX2 competitor (0.001 to 5 mg/mL).
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CD47-derived TAX2 peptide directly  
binds TSP-1
We further investigated whether the CD47-derived 
peptide, proposed using molecular modeling, directly 
binds to TSP-1 using an ELISA binding assay with biotin-
labeled peptides (Fig. 1F). The results highlighted that 
the TAX2 peptide binds to immobilized TSP-1 whereas 
the scrambled peptide does not. The specificity of the 
molecular interaction was controlled by competition with 
the corresponding non-biotinylated peptide. Competitive 
binding occurred in a dose-dependent fashion supporting 
this result (Fig. 1G). Consistently, the ability of TAX2 
to bind TSP-1 was also confirmed by surface plasmon 
resonance and microscale thermophoresis (data not 
shown). These data demonstrate that the newly discovered 
CD47-derived peptide directly binds to TSP-1, and could 
prevent its endogenous interaction with CD47.
TAX2 prevents angiogenesis both in vitro 
and ex vivo
As TSP-1 or TSP-1-derived peptides that bind 
to CD47 have been extensively reported to inhibit 
angiogenesis [12, 25], we investigated whether TAX2 
treatment could rescue angiogenesis using in vitro and 
ex vivo models. First co-immunoprecipitation assays were 
carried out to confirm that TAX2 specifically prevents 
TSP-1 binding to CD47 in human primary endothelial 
cells (Fig. 2A). However, TAX2 does not affect TSP-1 
binding to soluble partners such as FGF-2 and VEGF 
nor its ligation to other membrane receptors such as β1 
integrin and LRP-1 (Fig. S1) [30, 31]. As endothelial 
cell migration is critical to form blood vessels [32], a 
wound-healing assay was then conducted to quantify 
endothelial cell migration under TAX2 treatment. Contrary 
to our initial expectation, a reduced migration rate was 
observed when endothelial cells were treated by the 
CD47-derived peptide compared to control (Fig. 2B). 
Endothelial cell migration was also assessed using 
a Boyden chamber assay (Fig. 2C). TAX2 inhibited 
endothelial cell migration by 50% in this 3D-like system, 
consistent with the results obtained with the 2D wound-
healing model. A dose-response assay showed that the 
optimal inhibition is reached at a 100 μM concentration 
of TAX2 (data not shown). The unexpected inhibition of 
endothelial cell migration induced by TAX2 suggests that 
the newly characterized TSP-1:CD47 antagonist could act 
as prospective anti-angiogenic agent. To investigate the 
functional consequences of the CD47-derived peptide on 
microvascular network formation, we first conducted an 
in vitro assay allowing lumen formation by HUVECs on 
matrigel. As shown in Fig. 2D (left and middle panels), 
TAX2 inhibited the formation of a pseudo-tube network 
by 40% as assessed by quantification of total network 
length. Accordingly, the formation of branching points, 
capillary tubes and nodal structures was also decreased 
under TAX2 treatment (Fig. 2D, right panel). The decrease 
in endothelial cells ability to assemble in well-formed tube 
networks cannot be attributed to any cytotoxic effect of 
TAX2 (Fig. 2E). RNA interference-mediated knock-down 
of TSP-1 gene expression confirmed that TAX2 effects 
on lumen formation are specifically mediated by TSP-
1 targeting, as they were wholly abolished under TSP-1 
gene silencing (Figs. 2F and 2G). To confirm the results 
observed with this angiogenesis cell-based assay, TAX2 
properties were also evaluated in a more physiologically 
relevant setting using a mouse aortic ring assay [33]. As 
shown in Fig. 2H, microvessel sprouting from the aorta 
was markedly inhibited by the CD47-derived peptide, 
supporting its unpredicted but exciting anti-angiogenic 
effect.
TAX2 anti-angiogenic properties are mediated 
by TSP-1 binding to CD36
The anti-angiogenic properties of TAX2 were 
unexpected since TSP-1 binding to CD47 was mainly 
reported to promote arterial vasoconstriction and to 
inhibit VEGFR2 signaling [13, 14]. Considering that 
CD36 is also implicated in angiogenesis inhibition in 
response to soluble TSP-1 [11, 13], we investigated 
whether the anti-angiogenic effects of TAX2 could be 
mediated by CD36. As expected, we found that CD36 
is highly expressed in HUVECs (Fig. 3A). The amount 
of TSP-1 co-immunoprecipitated with CD36 increased 
by 3-fold in the presence of TAX2 (Fig. 3B), indicating 
that TAX2 enhances TSP-1 binding to CD36 in HUVECs. 
Since VEGFR2 can associate as a dimer with a CD36/
β1 integrin complex to form a cluster of membrane 
receptors regulating angiogenesis [13, 34], we further 
investigated the ability of TAX2 to inhibit VEGF-
induced activation of VEGFR2. As shown in Fig. 3C (left 
panel), TAX2 partially reverses VEGF-induced VEGFR2 
phosphorylation in HUVECs. This effect may be due to the 
association of activated VEGFR2 to a CD36-containing 
complex, as revealed by CD36 co-immunoprecipitation 
assays (Fig. 3C, right panel). Consistent with these 
data concerning VEGFR2 phosphorylation state, TAX2 
treatment also decreases cGMP production by endothelial 
cells after NO stimulation by around 25% (Fig. S2). 
Furthermore, the ability of TAX2 to prevent endothelial 
cell migration (Fig. 3D) and formation of capillary 
structures (Figs. 3E to 3G) is wholly reversed in the 
presence of a CD36 blocking antibody. Altogether, these 
data demonstrate that TAX2 promotes TSP-1 binding to 
CD36-containing complexes, leading to disruption of 
VEGFR2 signaling.
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Figure 2: TAX2 peptide impairs endothelial cell migration and inhibits angiogenesis in vitro and ex vivo. A. HUVECs 
were treated with TAX2 (100 μM) or scrambled peptide (Ctrl, 100 μM). CD47 was immunoprecipitated from total protein lysates using 
anti-CD47 (clone B6H12) and non-specific IgGs were used as a negative control. Immunocomplexes were then submitted to SDS-PAGE 
and immunoblotted (IB) using specific TSP-1 and CD47 antibodies. Histogram represents the quantification of co-immunoprecipitated 
TSP-1 relative to immunoprecipitated CD47. Results are expressed as percentage compared to control (n = 3 separate experiments, t test). 
B. HUVECs (1 × 105 per well) were grown at confluence and then cell proliferation was inhibited by incubating with 10 μg/mL mitomycin 
C for 2 h. Migration assays were performed for 9 h with or without TAX2 peptide (100 μM), as described in Materials and Methods. 
Photographs (100×) were taken every 3 h. Graph represents the quantification of the wounded area. Each value is the mean of 3 independent 
experiments, each performed in quadruplicate. C. HUVECs (5 × 104 per well) were plated into the upper compartment of a Transwell 
membrane and incubated for 12 h in EGM-2 in the presence of 100 μM TAX2 peptide. Hoechst-stained migrating cells attached on outside 
surface of the top chamber were photographed (20× objective) and counted. Results are expressed as percentage of migrated cells as 
compared to control. Each value represents the mean of 5 independent experiments, each performed in triplicate.*p < 0.05, compared to 
control; t test. D. HUVECs (5 × 104) were cultured on matrigel layers in control conditions (Ctrl) or in the presence of TAX2. After 8 h 
incubation, HUVEC tube-like formation was observed on an inverted microscope (40×) and quantification of network total length was 
done using ImageJ software. Numeration of branching points, tubes and nodal structures was conducted using S.CORE system. Data are 
expressed as the mean ± SE from at least 3 independent experiments, each performed in triplicate. 
(Continued )
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TAX2 induces extensive melanoma 
tumor necrosis in vivo
To investigate whether TAX2 could prevent 
tumor development by inhibiting angiogenesis, B16F1 
melanoma cells were subcutaneously inoculated in the 
left flank of C57BL/6 mice prior to three intraperitoneal 
administrations of TAX2 at days 3, 5 and 7. No significant 
modification in the measured median tumor volume was 
found for TAX2-treated mice compared to control mice 
during early stages of tumor development (Fig. 4A). 
However, mice treated with the CD47-derived peptide 
exhibited a substantial tumor necrosis at day 20 after 
tumor challenge (Fig. 4B). Tumor necrosis was visualized 
upstream through a multimodal imaging approach 
combining magnetic resonance imaging (MRI) analysis 
of isolated tumors (Fig. 4C) and quantitative micro-
computed tomography (μCT) imaging of mice (Fig. 4D). 
The manual measurement of tumor size did not give 
rise to any differences between TAX2-treated mice and 
control mice (Fig. 4A). However, quantitative imaging 
highlighted that the CD47-derived peptide could decrease 
tumor proper volume. Indeed, both MRI and μCT 
highlighted a large central necrotic area inside tumor 
masses from TAX2-treated mice whereas such necrotic 
cores remained much more restricted for control mice 
(Figs. 4C and 4D, see volume quantification bars under 
the images). Furthermore, these imaging observations 
were correlated to histopathological HPS staining showing 
that the necrotic area in TAX2-treated mice was increased 
by about 3-fold compared to control mice (Fig. 4E). 
Interestingly, neither μCT imaging of healthy organs 
nor mice dissections highlighted any sign of thrombosis, 
hemorrhage or embolism (data not shown).
TAX2 peptide substantially disturbs melanoma 
tumor vascularization in vivo
To determine whether tumor necrosis could be due 
to TAX2-induced inhibition of tumor angiogenesis, we 
performed a longitudinal follow-up of melanoma allograft 
angiography using μCT monitoring after intravenous 
injection of an alkaline earth-based nanoparticulate 
contrast agent [35]. While vascular structures were 
easily visualized within tumors of control mice at day 7 
after tumor challenge, blood vessels were undetectable 
within tumors of TAX2-treated mice (Fig. 5A, top 
panel). Intratumoral vascularization remained prominent 
within growing tumors of control mice, while it appeared 
restricted to tumor periphery under TAX2 treatment at day 
Figure 2: (Continued) E. HUVEC viability was assessed and expressed as percent compared to control treatment (t test, ns, not significant). 
F. Total RNAs were purified from HUVECs transfected with non-silencing siRNA (siCtrl) or siRNA targeting TSP-1 (siTSP-1). The 
transcriptional level of TSP-1 was assessed by RT-PCR and normalized to β-actin. Numbers under the gel indicate the fold change as 
compared to siCtrl cells used as reference. G. Tube formation assay was performed as described above. HUVECs transfected with siRNA 
sequences (siCtrl and siTSP-1) were allowed to form tubes on matrigel during 8 h in presence or absence of TAX2 (*, p < 0.05; ns, not 
significant; t test). H. Aortic ring assays were performed as described in the experimental procedure. After 6 days incubation in the presence 
of 100 μM TAX2 or control peptide (Ctrl), images were taken with an inverted microscope (40×) and microvessel area was quantified using 
ImageJ software. Insets from control conditions (arrowhead) and TAX2 treatment (star) highlight that the microvessel sprouting in matrigel 
was inhibited by TAX2 (zoomed in 200%). *, p < 0.05, compared to control (t test).
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Figure 3: Anti-angiogenic properties of TAX2 are mediated by TSP-1 binding to CD36. A. Expression of CD36 in HUVECs 
was assessed by immunoblotting (left panel) and immunofluorescence staining (right panel, red). Nuclei were counterstained with DAPI 
(blue). B. HUVECs were incubated with 100 μM cyclic TAX2 or in control conditions for 24 h. Then, CD36-containing complexes 
were co-immunoprecipitated from whole cell extracts (non-specific IgGs were used as a negative control for immunoprecipitation). 
Immunocomplexes were submitted to SDS-PAGE and immunoblotted (IB) by using specific antibodies for TSP-1 and CD36. The presence 
of TSP-1 in immunocomplexes was quantified by densitometric analysis relative to immunoprecipitated CD36. C. VEGFR2 phosphorylation 
induced by VEGF in the presence of TAX2. After overnight serum starvation, HUVECs were pre-treated with 100 μM TAX2 or control for 
12 h, then incubated with 30 ng/mL VEGF for 5 min. Whole cell lysates (left panel) or immunoprecipitated CD36-containing complexes 
(right panel) were submitted to SDS-PAGE and immunoblotted (IB) using anti-p-VEGFR2 (Y1175), anti-VEGFR2 and anti-β-actin or 
anti-CD36 antibodies. Upper numbers indicate the value of pVEGFR2/VEGFR2 ratio by densitometry (n = 3). D. Transwell migration 
assay was performed as described for Fig. 2C. HUVECs were allowed to migrate for 12 h under TAX2 or control treatment (100 μM) and 
with/without anti-CD36 blocking antibody (10 μg/mL). Non-reactive IgG1 serves as control for anti-CD36 treatment. Data are expressed 
as the mean ± SE (n = 3; *p < 0.05, ANOVA). E-G. HUVECs were incubated for 12 h in endothelial cell growth medium with 100 μM 
TAX2 or control peptide and with/without anti-CD36 blocking antibody (non-specific IgG1 serves as control). Tube formation assay was 
performed as described for Fig. 2D. Quantification of total tube-like network length was realized using ImageJ software E. Branching 
points F. and nodal structures G. were numbered using the S.CORE web-based system. Data are expressed as the mean ± SE (n = 3;  
*p < 0.05, ANOVA).
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Figure 4: TAX2 induces central tumor necrosis in a mouse melanoma allograft model. A. 2.5 × 105 melanoma B16F1 cells 
were subcutaneously injected into the left side of C57BL/6 mice. Control (Ctrl, open circle) or TAX2 (filled box) peptide (10 mg/kg) was 
intraperitoneally injected at days 3, 5 and 7. Tumor volume was measured with a caliper as described in Materials and Methods. Graph 
represents tumor volume measurements at day 12 after melanoma cell injection. Horizontal lines, median (n = 54, Mann-Whitney test). 
B. Tumor photographs at day 20 from 2 mice treated with scrambled (Ctrl, left panel) or TAX2 (right panel) peptide. C. Ex vivo MRI 
analysis of isolated tumors at day 12 after tumor challenge. Top panel: 2D virtual slice at the center of tumor volume. Bottom panel: Tumor 
3D reconstruction (orange: tumor, purple: necrotic area). Horizontal bars show the respective proportions of necrotic area and viable 
tumor tissue as quantified using Amira 5.4.3 software (representative of n = 10). D. μCT analysis of mice at day 14 after tumor challenge: 
tri-dimensional reconstruction after segmentation of melanoma tumor (blue) and the associated necrotic core (green) using Amira 5.4.3 
software. Horizontal bars show distribution of necrotic and viable parts within tumor volume (representative of n = 10). E. HPS staining of 
tumor sections showing tumor necrosis (dotted line). Insets (correspond to black rectangle in tumor sections, zoomed ×100) highlight the 
dense tumor tissue and its vascularization in viable areas (V) and cellular debris in the necrotic area (N) Tumor periphery is surrounded by 
a fibrotic capsule region (C). Histogram: quantification of the necrotic area relative to total tumor surface on each HPS-stained histological 
section using ImageJ software. Data are expressed as the mean ± SE (*p < 0.05, t test).
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Figure 5: TAX2 disturbs tumor angiogenesis. A. 2.5 × 105 melanoma B16F1 cells were subcutaneously injected into the left side 
of C57BL/6 mice, then intraperitoneal administrations of scrambled (Ctrl, left panel) or TAX2 (right panel) peptide (10 mg/kg) were 
performed at days 3, 5 and 7. Intravenous injections of an alkaline earth-based contrast agent (100 μL) were performed before mice 
imaging at days 7, 10 and 14 to allow a longitudinal follow-up of tumor angiography through μCT analysis. Black arrows illustrate 
contrast enhancement of intratumoral blood vessels; white arrow indicates tumor necrosis (representative of n = 5). B. Tridimensional 
reconstructions of tumors at day 14. Melanoma tumor (purple) and the associated vascular network (orange) were segmented using Amira 
5.4.3 software. C. Color-coded representation of tumor-associated blood vessel network depending on structure thickness (Amira 5.4.3 
software). Thin structures are represented in blue, which changes to green and red when the vessel diameter increases. D. Quantification 
of tumor-associated blood vessel mean length, volume and radius using Amira 5.4.3 software. Data are expressed as the mean ± SE  
(*p < 0.05, t test). E. CD31 immunostaining of tumor frozen sections. Quantification was done using ImageJ software, and results are 
expressed as a percentage of control MVD and blood vessel mean size (mean ± SE, n = 6, t test).
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10 (Fig. 5A, middle panel). At day 14, a central vascular 
network within tumors from TAX2-treated mice was still 
lacking and a wide hemorrhagic area corresponding to the 
previously described necrotic zone was observed (Fig. 5A, 
bottom panel). Tridimensional reconstructions 14 days 
after tumor challenge revealed a mature peritumoral and 
intratumoral vascular network in control mice (Fig. 5B, 
upper panel). In contrast, after TAX2 treatment, tumor 
vasculature appeared highly anarchic and discontinuous, 
only at the tumor surface, surrounding a central 
hemorrhagic area (Fig. 5B, lower panel). Segmentation 
and quantification of the tumor-associated vascular 
network revealed that TAX2 induces a 2-fold reduction in 
blood vessel mean volume, as the treatment significantly 
decreased both the length and diameter of blood vessels 
(Fig. 5C, 5D and Supplementary movie 2). In accordance 
with these results, CD31 immunostaining of tumor 
cryosections reveals a 60% diminution in intratumoral 
MVD associated to a diminution in vessel size (Fig. 5E). 
In light of these observations and in consistence with 
results from in vitro and ex vivo assays, we established 
using μCT longitudinal analysis that TAX2 acts as a new 
anti-angiogenic agent.
TAX2 treatment delays growth of human 
pancreatic carcinoma xenografts
While significant defects in vascularization and 
extensive tumor necrosis were observed in the syngeneic 
subcutaneous melanoma model, there was no change 
regarding apparent tumor volume (Fig. 4A). As this 
conflicting result might be explained by the notorious 
invasiveness of the B16 model, we decided to extend the 
results in a less aggressive model of human pancreatic 
carcinoma xenograft. Intraperitoneal administrations of 
TAX2 after tumor pre-establishment induced a strong 
delay in MIA PaCa-2 subcutaneous xenografts growth 
(Fig. 6A); resulting in a 2-fold decrease of tumor volume 
at day 38 after cells inoculation (Figs. 6B and 6C) while 
mice did not exhibit any other clinical sign or weight 
loss (Fig. 6D). Mouse dissections disclosed a correlation 
between reduced tumor volume and decreased tumor 
vasculature under TAX2 treatment (Fig. 6E). Analysis 
of tumor angiography by μCT revealed that intratumoral 
blood vessels were undetectable within subcutaneous 
xenograft at day 24 after tumor challenge (Fig. 6F, left 
panel), when no differences in measured tumor volume 
were observed at this stage (Fig. 6A). Longitudinal follow-
up until day 38 showed prominent intratumoral blood 
vessels within growing tumors of control mice, while 
decreased tumor growth was accompanied by a striking 
alteration of tumor vascularization under TAX2 treatment 
(Fig. 6F, middle and right panels). Tridimensional 
reconstructions at day 38 after tumor challenge 
confirmed that TAX2 administrations strongly inhibit 
tumor-associated vascular network (Fig. 6G). Altogether, 
these data presents TAX2 peptide as a new anti-angiogenic 
agent suppressing tumor vasculature.
DISCUSSION
In the present study, we used molecular docking 
experiments to identify an innovative dodecapeptide 
sequence derived from the cell surface receptor CD47 that 
antagonizes TSP-1:CD47 interaction. We demonstrate 
that the in silico-designed peptide, called TAX2, exhibits 
unexpected anti-angiogenic properties in vitro and ex vivo 
and induces extensive melanoma tumor necrosis in vivo 
by inhibiting tumor angiogenesis. Moreover, TAX2 
peptide also significantly inhibits tumor growth in a 
human pancreatic carcinoma xenograft model. These 
results were obtained by means of a large number of 
animals and samples using innovative multimodal and 
multi-scale imaging approaches that were supported by 
histopathological staining.
The anti-angiogenic properties of TAX2 were quite 
surprising and unexpected since TSP-1 binding to CD47 
has been mainly reported to promote vasoconstriction and 
limitation of angiogenesis. Indeed, by using TSP1-derived 
peptides and recombinant fragments of TSP-1, Isenberg 
and collaborators demonstrated that the anti-angiogenic 
activity of TSP-1 is mainly mediated via binding to 
CD47, resulting in inhibition of NO-induced activation of 
guanylate cyclase [25]. Besides the modulation of cyclic 
nucleotide levels, TSP-1 CBD ligation to CD47 was 
recently reported to disrupt the constitutive association 
of CD47 with VEGFR2 in endothelial cells, resulting 
in inhibition of VEGFR2 activation and downstream 
signaling [14].
Here, we do not dispute the fact that TSP-1 is 
capable of inhibiting angiogenesis by different routes. 
However, we are convinced that the selective inhibition 
of TSP-1 interaction with CD47 can induce a previously 
unpredicted overall anti-cancer response, to be explored 
and deciphered. Although the anti-angiogenic and anti-
tumor properties of TAX2 were initially not predicted, they 
are nevertheless consistent with results previously reported 
by Maxhimer and collaborators [36] who emphasized the 
therapeutic value of blocking TSP1:CD47 interaction by 
using the same experimental in vivo melanoma model. 
This study also suggests that favorable combination 
of TAX2 with radiotherapy would be promising to 
improve therapeutic response and treatment tolerance. 
Interestingly, the effects of TAX2 appear to be restricted to 
the tumor-associated environment overexpressing TSP-1, 
as no signs of thrombosis, hemorrhage or embolism 
were observed in healthy organs in both syngeneic 
melanoma and human pancreatic carcinoma models. 
We are convinced that the unexpected effects of TAX2 
could be attributable to an intense matrix remodeling 
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Figure 6: TAX2 inhibits growth of human pancreatic carcinoma tumor xenografts. A. 3 × 106 pancreatic carcinoma MIA 
PaCa-2 cells were subcutaneously injected into the left side of BALB/C nu/nu mice. Control (Ctrl) or TAX2 peptide (10 mg/kg) was 
intraperitoneally injected 3 times a week for 4 weeks starting at day 10 after tumor challenge. Tumor volume was measured with a caliper 
as described in Materials and Methods. Histogram represents the evolution of tumor xenograft volume. Data are expressed as apparent 
median tumor volume ± SE (*p < 0.05; Mann-Whitney test; n = 15 from days 10 to 24, n = 11 at day 31, n = 9 at day 38). B. Tumor volume 
measurements at day 38 after pancreatic tumor cells injection. Horizontal lines, median (n = 9; Mann-Whitney test; *p < 0.05). C. Tumor 
photographs at day 38 after pancreatic tumor cells injection. Dotted lines show tumor contours. D. Mouse mean weight evolution for control 
(Ctrl, open circle) and TAX2-treated (filled box) groups. E. Tumor dissection photographs at day 38 for 2 mice from control group (Ctrl, top 
panel) or TAX2-treated group (bottom panel). F. μCT imaging of mice at days 24, 31 and 38 after intravenous injection of an alkaline earth-
based contrast agent (100 μL) allowing tumor angiography analysis. Black arrows illustrate contrast enhancement of intratumoral blood 
vessels (representative of n = 5). G. Tridimensional reconstructions of tumors at day 38. Human pancreatic carcinoma xenograft (blue) and 
the associated vascular network (red) were segmented using Amira 5.4.3 software.
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occurring within tumor-associated microenvironment, 
in which matricellular proteins, including TSP-1 and 
CD47 ligands, may reach bioavailable concentrations 
that overcome physiological levels. By disregarding the 
main changes in the molecular balances between the 
respective ligands occurring in the highly reactive tumor 
microenvironment, we impede our thinking and limit our 
ability to improve existing treatments. TSP-1 was indeed 
reported to be over-expressed in tumor stroma [37], and its 
contribution through CD47 ligation remains controversial 
in this context due to the pleiotropic nature of TSP-1 
and its ability to induce opposite effects in different host 
organ environments [16, 23]. In myeloma, the potential 
importance of targeting CD47-TSP-1 axis has already 
been highlighted [38]. Consistent with our data, CD47 was 
found to be elevated in clinical melanoma samples and 
delivery of siRNA targeting CD47 was recently reported 
to effectively inhibit melanoma tumor growth and lung 
metastasis [39]. Moreover, recent data pointed out that 
CD47 mRNA expression in patients are correlated with 
decreased survival in several cancer types and antibody 
blockade of CD47 yielded promising results in mice 
bearing human xenografts reducing tumor growth as well 
as metastasis [40]. Strategies based on CD47 blockade 
are also currently under development giving promising 
results in multiple pancreatic cancer preclinical models 
[41]. However, caution must be raised when comparing 
TAX2 biological effects to previous results obtained by 
using blocking CD47 antibodies. TAX2 treatment only 
targets TSP-1 and may not affect CD47 association with 
other ligands such as integrins or SIRP-α as the structures 
involved are not redundant with those implicated in 
the molecular complex interface (Fig. S3) [4, 42]. 
Moreover, anti-CD47 IgG may also induce Fc-mediated 
effects such as antibody-dependent phagocytosis or 
cytotoxicity. Using TAX2 provides new opportunities to 
bypass the problem of existing molecules blindly targeting 
CD47 towards its ligands that may have major effects on 
tumorigenesis.
In addition to the putative effects that may be 
due to CD47 association with its co-receptors, TAX2-
bound TSP-1 also remains able to bind a wide variety of 
ligands through the other domains of the multi-modular 
protein. Among these domains, a central region of TSP-1 
called 3TSR (three TSP-1 type 1 repeats) binds to the 
CD36 membrane receptor, also leading to inhibition of 
angiogenesis. Indeed, CD36 ligation by TSP-1 is known 
to induce an anti-angiogenic response by promoting 
CD36 association with β1 integrin and VEGFR2 
dimer in a tripartite complex, resulting in decreased 
VEGFR2 phosphorylation after VEGF stimulation [13]. 
Physiological plasmatic TSP-1 concentration at around 
100 pM favors TSP-1 ligation to CD47, as the binding 
affinity is higher compared to CD36 binding [43]. To 
explain our apparently contradictory results, we 
hypothesized that TAX2 peptide inhibiting TSP-1: 
CD47 interaction may increase the amount of 
bioavailable soluble TSP-1 that is free from CD47 
engagement, thus stimulating TSP-1 3TSR binding to 
CD36 and resulting to an anti-angiogenic response. 
Using CD36 co-immunoprecipitation experiments, 
VEGFR2 phosphorylation assays and validated 
CD36 blocking antibodies, we established that TAX2 
induced a shift in TSP-1 binding from CD47 to 
CD36 (Fig. 7). Accordingly, we propose that TAX2 
prevents VEGFR2 activation by VEGF and inhibits 
subsequent NO-cGMP signaling, leading to inhibition 
of endothelial cell migration and abrogation of the 
formation of capillary-like structures. Furthermore, we 
found using TSP-1 ELISA assay that soluble TSP-1 
reaches nanomolar concentrations compatible with CD36 
activation in our endothelial cell environment (data not 
shown) [25]. CD36 has already been considered as a 
target of interest in the development of TSP-1-based 
anti-angiogenic therapies. Dawson and colleagues first 
described in 1999 a modified TSP-1 type 1 repeats-derived 
nonapeptide (since referenced as ABT-510) exhibiting 
strong anti-angiogenic and anti-neoplasic activities 
[44]. By modulating endothelial cell proliferation and 
migration as well as apoptosis in CD36-expressing cancer 
cells [45], ABT-510 targets both tumor cells and the 
associated tumor vascular network. Indeed, significant 
effects of ABT-510 on tumor growth and vascularization, 
especially microvessel density, were reported in vivo in 
many cancers including glioma [46], ovarian carcinoma 
[45], Lewis lung carcinoma [47] and bladder cancer [48]. 
Several phase I and phase II clinical trials have been 
conducted with ABT-510 since 2005. These trials have 
sometimes led to intricate and nuanced outcomes mainly 
due to a lack of clinical activity when used as a single 
agent with frequently observed severe adverse events 
such as thrombosis and pulmonary embolism [49, 50]. 
By concomitantly inhibiting TSP-1 binding to CD47 
and enhancing its ligation to CD36, TAX2 may induce a 
weaker anti-angiogenic response than the one resulting 
from 3TSR stimulation of CD36, which might therefore 
significantly reduce the risk of thrombosis.
In the subcutaneous B16 melanoma model, systemic 
administrations of TAX2 peptide during the early stages 
of tumor growth induces a delayed but extensive tumor 
necrosis, as evidenced by MRI and μCT. Regarding the 
results obtained in our in vitro and ex vivo models, we 
assume that TAX2-related effects may mostly be attributed 
to stromal cells in the TSP-1-enriched tumor stroma, 
especially through endothelial cell targeting. Analysis 
of tumor angiography highlighted that tumor-associated 
vascular network appears significantly disrupted and 
unstructured as a delayed consequence of TAX2 treatment, 
which was consistent with the results obtained from the in 
vitro morphogenesis assay.
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Given the fact that TAX2 anti-cancer effects were 
reproduced in immunodeficient BALB/C nu/nu athymic 
mice, the eventual immunological contribution that 
may be involved in TAX2-derived anti-tumor effects 
could be de-emphasized. In the less aggressive MIA 
PaCa-2 pancreatic carcinoma xenograft model, systemic 
administrations of TAX2 peptide decrease growth of pre-
established subcutaneous tumors 2-fold by considerably 
altering tumor-associated vasculature. Consistent with 
our proposed mechanism of action that involves an 
enhanced activation of the TSP-1/CD36 axis under TAX2 
treatment, these experimental data are also coherent 
with previous work underlying the anti-angiogenic and 
anti-tumor potential of the CD36-binding 3TSR module 
of TSP-1 in human pancreatic cancer models [51, 52]. 
Indeed, the relevance of targeting VEGFR signaling in 
pancreatic cancer has also been demonstrated [53]. An 
obvious approach for VEGF inhibition is to decrease 
the availability of ligand (VEGF), as demonstrated by 
bevacizumab, a humanized murine anti-human VEGF-A 
monoclonal antibody that has been used in the treatment of 
pancreatic cancer together with other chemotherapy agents 
[54, 55]. In the MIA PaCa-2 xenograft model, our results 
show that TAX2 administrations led to higher inhibition 
rates compared to 5 mg/kg bevacizumab intraperitoneally 
injected twice weekly [56], suggesting that TAX2 peptide 
may be useful upon development of tumor resistance 
against bevacizumab and other conventional anti-
angiogenic therapies. Indeed, recent studies showed that 
anti-VEGF treatment could make tumor more aggressive 
Figure 7: TAX2 induces a shift in TSP-1 binding from CD47 to CD36. A. In physiological conditions, most of TSP-1-related 
effects on vascular function are mediated by TSP-1 carboxy terminal domain interaction with CD47 receptor. B. Under TAX2 treatment 
preventing TSP-1:CD47 interaction, binding of the 3TSR module of TSP-1 to CD36 receptor is promoted, thus leading to an overall  
anti-angiogenic response (NTD, N-terminal domain; Col, procollagen-homology domain; CBD, carboxy terminal cell binding domain).
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and metastatic [57]. While the mechanisms and mediators 
of this phenomenon are not yet all understood, emerging 
evidence indicates that angiogenesis targeting agents 
may induce a “metastatic switch” as a result of hypoxia 
in certain experimental conditions [58]. Interestingly, 
TAX2 did not increase metastasis formation considering 
an experimental model of lung metastasis using invasive 
B16F10 melanoma cells (data not shown), confirming 
that using TAX2 alone or in combination with other 
chemotherapeutic agents may be highly relevant for future 
therapeutic approaches.
Overall, we have developed and characterized an 
innovative and non-obvious molecule that targets TSP-1 
at the CD47 binding site and exhibits unpredicted but 
exciting overall anti-cancer properties in vivo. These data 
emphasize the therapeutic value of blocking TSP1:CD47 
interaction for inhibiting tumor vascular network. This 
challenges the current dogma on TSP-1 and provides new 
conceptual insight that could supply innovative therapeutic 
approaches against malignant diseases.
MATERIALS AND METHODS
Cell culture, reagents and antibodies
B16F1 cancer cell line was obtained from the 
American Type Culture Collection (ATCC) and maintained 
in RPMI-1640 medium (Gibco, Life Technologies, Saint-
Aubin, France) supplemented with 10% fetal bovine serum 
(FBS). CD47 expression in B16F1 cells was checked by 
immunoblot. MIA PaCa-2 cell line was obtained from 
ATCC and maintained in Dulbecco’s Modified Eagle’s 
Medium (Gibco) supplemented with 10% FBS and 2.5% 
horse serum. HUVECs pre-screened for angiogenesis 
and vascular cell health markers (including eNOS and 
VEGF-R2) were purchased from Lonza Clonetics (Basel, 
Switzerland) and maintained in complete endothelial 
growth medium (EGM-2, Lonza) at early passages (up 
to 4). All cell lines were authenticated before experiments 
according to the provider’s protocol. Cell viability 
and cell proliferation were assessed using UptiBlue 
Viable Cell Counting Kit (Uptima, Interchim, France). 
Thrombospondin from human platelets and human 
recombinant VEGF-165 were purchased from Calbiochem 
(Merck Millipore, Darmstadt, Germany) and PromoKine 
(PromoCell, Heidelberg, Germany), respectively. Anti-
biotin antibody (#MB-9100) was purchased from Vector 
Laboratories (Abcys, Les Ulis, France). Anti-CD47 (clone 
B6H12, #556044) was from BD Pharmingen (Le Pont-
de-Claix, France). Anti-TSP-1 (clone A6.1, #ab1823) 
and anti-β1 integrin (clone BV7, #ab7168) were from 
Abcam (Paris, France). Anti-LRP light chain (clone 
5A6, #438192) and heavy chain (clone 8G1, #438190) 
were from Calbiochem. Anti-CD36 (clone FA6–152, 
#sc-52645), anti-β-actin (#sc-1616),  anti-p-VEGFR2 
(Y1175, #CC1028), anti-VEGFR2 (#CC1020), anti-
FGF-2 (clone C-18, #sc-1360), anti-VEGF (clone C-1, 
#sc-7269) and normal mouse IgG (#sc-2025, used as 
a control for immunoprecipitation) were from Santa 
Cruz Biotechnology (Tebu-bio, Le Perray-en-Yvelines, 
France). HRP-linked anti-mouse IgG (#7076S) and 
anti-rabbit IgG (#7074S) used as secondary antibodies 
for Western blots were purchased from Cell Signaling 
Technology (Ozyme, Saint-Quentin-en-Yvelines). 
HRP-linked anti-goat IgG (#A5420), DEA-NONOate 
(2-(N, N-Diethylamino)-diazenolate 2-oxide sodium salt 
hydrate) and IBMX (3-isobutyl-1-methylxanthine) were 
obtained from Sigma-Aldrich (Saint-Quentin Fallavier, 
France). Anti-CD31 antibody (clone MEC 13.3) used 
for immunohistochemistry was from BD Pharmingen 
(#557355) and biotinylated anti-rat IgG (#BA-4001) used 
as secondary antibody was Vector Laboratories (Abcys). 
Secondary Alexa Fluor 568-conjugated antibodies and 
Prolong Gold antifade reagent with DAPI were from 
Molecular Probes (Invitrogen, Cergy-Pontoise, France).
Molecular docking and simulations
Rigid protein-protein docking of CD47 (PDB ID 
code 2JJS [42], chain C) was performed against an open 
conformation of TSP-1 CBD, as previously determined 
by normal mode analysis [29] using the GRAMM-X web 
server v1.2.0. A refinement of the resulting orientations 
was further performed using RosettaDock (Rosetta 3.4 
software). The structure of the CD47-derived peptide 
(TAX2) was predicted using the PEP-FOLD online 
resource in order to verify that the chosen sequence 
mimics the native helix conformation. Predicted structures 
of this linear peptide and of its cyclic disulfide analogue 
(manually edited and minimized) were compared to 
the corresponding X-ray structure in 2JJS using VMD 
software. Molecular dynamics simulations in explicit 
solvent (TIP3P) were performed on both peptides using 
NAMD software together with the CHARMM27 force 
field, in the NPT ensemble at 293 K - 1 atm, with a cut-
off of 11 Å for long-range interactions. The relative 
flexibility of both peptides was assessed by means of Root 
Mean Square Deviation (RMSD) calculations. Molecular 
docking between the minimized cyclic peptide and the 
TSP-1 open conformation was done using Autodock 
4.2 software (population size of 200, 10 × 106 energy 
evaluations, 250 LA-GS runs). Figures and graphs were 
generated using VMD and R software, respectively.
Designed peptides
The CD47-derived linear dodecapeptide 
(IEVSQLLKGDAS), its cyclic disulfide analogue 
(CEVSQLLKGDAC), the scrambled dodecapeptide 
used as a control (LSVDESKAQGIL) as well as the 
corresponding biotinylated peptides were synthesized 
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and purified by Genecust (Dudelange, Luxembourg). 
Each peptide was controlled following synthesis for 
composition and purity through electrospray ionization-
mass spectrometry (ESI-MS) and HPLC. Disulfide bridge 
cyclisation was ensured by Raman spectroscopy. Peptides 
were solubilized in the appropriate medium for in vitro 
and ex vivo assays, or in normal saline solution (0.9% 
(w/v) NaCl) for in vivo experiments.
Binding of biotin-labeled peptides to 
immobilized TSP-1
Microtiter plates (Nunc, ThermoFisher Scientific, 
Courtaboeuf, France) were coated overnight at 4°C with 
0.5 μg TSP-1 in sodium carbonate-bicarbonate (BupH) 
buffer (Thermo Fisher Scientific). Plates were washed 
with PBS 0.1% BSA (Sigma-Aldrich) and non-specific 
sites were saturated during 30 min using 1% (w/v) 
BSA in BupH buffer. Biotin-labeled peptide (10 μg/
mL, determined after dose-response assay from 0.01 to 
100 μg/mL) was added in buffer containing 0.5% (w/v) 
BSA and incubated for 3 h at room temperature. Non-
labeled peptide (0.001 to 5 mg/mL) was used as selective 
competitor. Plates were washed with PBS containing 
0.1% (w/v) BSA and treated for 30 min with mouse anti-
biotin antibody. Bound antibody was quantified using the 
mouse IgG Elite Vectastain ABC kit (Vector Laboratories) 
followed by incubation with 1-Step Turbo TMB substrate 
as a chromogen (ThermoFisher Scientific). The reaction 
was stopped with 0.5 M H2SO4 and absorbance was read 
at 450 nm.
Protein extraction and Western blot analysis
Cells were harvested on monolayers, washed with 
ice-cold PBS and then solubilized in lysis buffer (50 mM 
HEPES, pH 7.6, 100 mM NaCl, 20 mM EDTA, 1% (v/v) 
Triton X-100, 0.5 mM PMSF) supplemented with Halt 
protease and phosphatase inhibitor cocktail (Thermo Fisher 
Scientific). The protein concentration was quantified using 
the BCA Assay kit (Uptima). Lysates were loaded on 10% 
polyacrylamide gels and separated by SDS-PAGE. Proteins 
were transferred to nitrocellulose membranes (Amersham 
Biosciences), blocked with dry milk solution (5% w/v) or 
BSA (5% w/v) for phospho-proteins and immunoblotted 
with indicated antibodies. Immunoreactive bands were 
revealed using ECL+ chemiluminescence kits (Amersham 
Biosciences) and analyzed with a ChemiDoc-XRS imaging 
station (Bio-Rad, Marnes-la-Coquette, France).
Co-immunoprecipitation assay
Protein lysates prepared in ice-cold lysis 
buffer or conditioned media were subjected to 
immunoprecipitation assay using the Pierce Co-IP 
kit (Thermo Fisher Scientific) according to the 
manufacturer’s protocol. 10 μg of antibody (anti CD47, 
anti-CD36, anti-FGF2, anti-VEGF, anti-β1 integrin 
and anti-LRP1 heavy chain) or non-specific IgGs were 
incubated with the delivered resin and covalently 
coupled. The antibody-coupled resin was incubated 
with whole HUVEC protein lysate overnight at 4°C 
under gentle agitation (no cross-linker was used to 
stabilize protein complexes before HUVEC lysis). 
Then the resin was washed and the protein complexes 
bound to the antibody were eluted. Immunoprecipitated 
protein complexes were solubilized under denaturing 
and reducing conditions, heated to 100°C for 5 min and 
analyzed by immunoblotting as described above.
Wound healing assay
HUVECs were allowed to grow to confluence in 
12-well plates and then incubated with 10 μg/mL 
mitomycin C at 37°C, 5% CO2 during 2 h to inhibit 
proliferation. The monolayer was wounded by scratching 
with a 200 μL pipette tip. Images were collected at 
different times using a phase contrast microscope with a 
20× objective coupled to a Nikon digital camera. Wound 
area was quantified using ImageJ software (3 photographs/
wound and 3 replicates for each condition).
Transwell assay
24-well Transwell cell growing chambers (8.0 μm 
pore size; Greiner Bio-one, Dutscher) were used to assess 
endothelial cell migration. HUVECs were seeded into the 
upper compartment and incubated at 37°C for 12 h, the 
lower chamber containing complete EGM-2 with 2% (v/v) 
FBS acting as the stimulus for migration. Non-migrated 
cells on the top side of the surface were eliminated with a 
cotton swab, then the migrated cells at the bottom of the 
membrane were fixed with methanol, stained with Hoechst 
33342 and visualized using a Zeiss inverted microscope 
(20× objective). Migration was quantified in 4 random 
microscopic fields per well using ImageJ software.
Endothelial tube formation assay
Pre-chilled 24-well plates were coated with 250 μL 
matrigel (BD Biosciences) and incubated at 37°C for 30 
min. HUVECs were plated at subconfluent densities in 
endothelial cell growth medium to form capillary-like 
structures. Pseudo-tubes formation was observed after 8 h 
incubation period using a Zeiss phase-contrast inverted 
microscope (20× objective; 4 photographs and 3 replicates 
for each condition). Total network length was quantified 
using ImageJ software. Branching points, nodal structures 
and tubes were assessed using the S.CORE web-based 
system for automatic image analysis (S.CO LifeScience, 
Hoehenkirchen, Germany).
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Small interfering RNA transfection
HUVECs were transfected with a pool of 
3 target-specific 20–25 nt TSP-1 siRNAs (Santa Cruz 
Biotechnology, #SC-36665) designed to knock-down 
gene expression. As a control, cells were treated with an 
equal amount of nonspecific control RNA (Dharmacon, 
Thermo Fisher Scientific). Transfection of synthetic RNA 
(200 nM siRNA or control) was done using Amaxa™ 
HUVEC Nucleofector™ kit according to the 
manufacturer’s protocol (Lonza). Following transfection 
with siRNA, cells were incubated for 24 h followed by the 
conditions indicated.
Reverse Transcription-PCR
RNA was extracted with RNeasy kit (Qiagen, 
Courtaboeuf, France) according to the manufacturer’s 
instructions. RNA (100 ng) from each sample was 
transcribed to cDNA using Verso cDNA kit (AB-1453/B) 
from ThermoFisher Scientific. Previously described PCR 
primers for TSP-1 [17] and β-actin [59] were synthesized 
by Eurogentec (Angers, France). Numbers of cycles were 
adjusted to ensure that amplifications were in a linear 
range. An aliquot of each PCR product was subjected to 
1.2% (w/v) agarose gel electrophoresis and visualized by 
staining with ethidium bromide.
Intracellular cGMP measurement
HUVECs (1 × 104 per well) were grown over 24 h in 
96-well plates containing EGM-2 full growth medium and 
then serum-starved in EBM-2 containing 0.1% (v/v) BSA 
over additional 24 h. Cells were then pre-treated during 
15 min with 100 μM TAX2 in EBM-2 without additives 
plus 0.1% (v/v) BSA before treatment with NO donor in 
presence of 1 mM IBMX as a phosphodiesterases inhibitor. 
After 10 min, intracellular cGMP levels were determined 
according to the manufacturer’s instructions using an 
enzyme immunoassay kit (Amersham Biosciences).
Animals
8-week-old female C57BL/6 mice (average body 
weight, 18–20 g) were purchased from Janvier Labs 
(Saint-Berthevin, France). 8-week-old female BALB/C 
nu/nu mice were supplied by Charles River Laboratories 
(L’Arbresle, France). Animals were kept in a room with 
constant temperature and humidity, and food and water 
were given ad libitum. Mice were acclimatized to our 
laboratory conditions for 1 week before starting the 
experiments. The in vivo experiments were conducted 
in conformity with institutional ethical guidelines of 
the University of Reims Champagne-Ardenne and the 
CNRS (Centre National de la Recherche Scientifique), 
in compliance with the European Directive 2010/63/UE. 
The French Ministry of Higher Education and Research 
approved protocols under references 02203.01 and 
02204.01.
Mouse aortic ring assay for endothelial 
cell sprouting
Thoracic aortae were excised from C57BL/6 mice 
and peri-adventitial fibro-adipose tissues were removed. 
Aortae were then cut into 1 mm rings, washed and 
transferred to 96-well tissue culture plates coated with 
100 μL per well of matrigel. Explants were then overlaid 
with additional 50 μL of matrigel. After polymerization, 
endothelial growth medium was added and then renewed 
every day. Digital images were taken on day 6 for 
quantitative analysis of vascular endothelial outgrowth 
using ImageJ software.
In vivo models
For the subcutaneous melanoma tumor model, 
suspensions of B16F1 cells (2.5 × 105 cells in 100 μL 
RPMI-1640 medium) were subcutaneously injected into 
the left flank of different randomized series of syngeneic 
C57BL/6 mice (n = 8–10 per group), as previously 
described [60]. Intraperitoneal administrations of peptide 
(10 mg/kg mouse weight) or controls (physiological 
serum 0.9% (w/v) NaCl or a scrambled peptide) were 
performed at days 3, 5 and 7. In human pancreatic 
carcinoma xenograft experiments, 3 × 106 MIA PaCa-
2 cells/mouse were implanted subcutaneously into the 
left flank of BALB/C athymic nude mice, then TAX2 
intraperitoneal treatments (10 mg/kg mouse weight) were 
performed 3 times a week during 4 weeks starting at 
day 10 after tumor cells inoculation. Tumor volume was 
determined according to v = 0.5 A × B2, where A denotes 
the largest dimension of the tumor and B represents the 
smallest dimension [61]. At days indicated, mice were 
sacrificed and tumors were surgically extracted and 
fixed in 4% paraformaldehyde for further morphologic 
studies and for magnetic resonance imaging, or frozen for 
immunohistochemistry. Mice were also weighed every 
2–3 days and daily checked for any modification in their 
behavior. Loss of 15% body weight was an indication 
for euthanasia as well as severe tumor necrosis, as it was 
sometimes associated with skin ulceration that would 
result in loss of body fluid and/or infection.
Histopathological analysis of tumors
Histological analysis of formaldehyde-fixed 
and paraffin-embedded tumors were performed on 
hemalun, phloxin and saffron (HPS) stained 3 μm thick 
sections prepared using routine histological methods. 
To assess tumor-associated microvessel density (MVD), 
CD31 immunostaining was performed on 5 μm thick 
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cryosections using biotin-labeled secondary antibody 
and streptavidin-HRP AEC detection system (Microm 
Microtech, Francheville, France), followed by hematein 
counter-coloration. Negative controls were done omitting 
the primary antibody. The necrotic part relative to total 
tumor surface for each tumor slice as well as MVD were 
quantified using ImageJ software.
Ex vivo MR imaging of tumors
Tumors were studied by magnetic resonance 
imaging (MRI) for visualization of tumor necrosis when 
the subcutaneous allografts reached a diameter of about 
0.8 cm (day 12). NMR ex vivo studies were performed on 
an 11.7 Tesla Bruker Avance DRX 500 system equipped 
with a micro-imaging probe (Bruker Biospin, Germany). 
High-resolution T1-weighted images were obtained 
with the following parameters: TR = 300 ms, TE = 
2.2 ms, 256 × 256 × 256 matrix and a 0.9 × 0.9 × 1.5 cm 
FOV. Image treatment, segmentation, tri-dimensional 
reconstruction and quantification were performed using 
ImageJ and Amira 5.4.3 (Visualization Sciences Group, 
Burlington, MA, USA) software.
μCT imaging of mice
Animals were anesthetized by isoflurane (Forene, 
Abbott France, Rungis, France) inhalation (3% for 
induction and 1–1.5% for maintenance) and then after 
placed in a carbon fibers bed. CT images were acquired 
on a dedicated small animal μCT scanner (Skyscan 1076, 
Bruker, Kontich, Belgium) while continuously rotating 
the camera by 180° with the following parameters: 50 kV, 
0.5 mm Al filter, 200 μA source current, 35 μm isotropic 
resolution, 180 ms exposure time, 4 projection images 
per 0.7° rotation step and a retrospective synchronization. 
The projections were reconstructed using a filtered 
backprojection algorithm using Skyscan software 
(NRecon, Skyscan). For tumor angiography analysis, 
an alkaline earth-based nanoparticulate contrast agent 
(Viscover ExiTron nano 12000, Miltenyi Biotec, Paris, 
France) was injected in the mouse tail vein. Mice were 
imaged during the next 30 min following injection, a 
period during which no reduction in contrast was observed 
[35]. Analysis of reconstructed images and quantification 
of the vascular network were performed using Amira 5.4.3 
software.
Statistical analysis
GraphPad Prism 5.0 software (GraphPad, La Jolla, 
CA) was used for all statistical analyses. Each result is 
representative of at least 3 independent experiments. Data 
are expressed as the mean ± SE. Significance was assessed 
using 2-tailed Student’s t test and analysis of variance 
(ANOVA) for in vitro and ex vivo studies; Mann-Whitney 
U test was used for in vivo experiments. For all tests, 
statistical significance was assumed when p < 0.05 (*).
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